Risperidone-associated prolactin elevation and markers of bone turnover during acute treatment

Jeffrey R. Bishop, Leah H. Rubin, James L. Reilly, Mani N. Pavuluri, John A. Sweeney

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Prolactin elevation has been proposed as a risk factor for low bone density and potentially osteoporosis in patients on long-term treatment with prolactin-elevating antipsychotics. Our objective was to study the acute effects of prolactin elevation on serum markers of bone formation and resorption in patients treated with risperidone. Thirty participants meeting Diagnostic and Statistical Manual of Mental Disorders fourth edition criteria for schizophrenia, major depressive disorder with psychotic features, or bipolar disorder with psychosis were enrolled. At baseline, subjects were antipsychotic free. Subjects were evaluated before and after 4 weeks of risperidone treatment. Assessments included symptom ratings along with testosterone, estradiol, prolactin, osteocalcin (marker of bone formation), and n-telopeptide crosslinks (NTx marker of bone resorption). Primary analysis examined the impact of risperidone treatment on change in the bone markers and hormone levels from pre to post treatment. Prolactin levels significantly increased from 12.1 ± 1.9 ng/ml to 65.7 ± 12.2 ng/ml after treatment (p < 0.001). NTx markers of bone resorption significantly decreased from 18.31 ± 1.49 nM bone collagen equivalent (BCE) before treatment to 15.50 ± 1.22 nM BCE after treatment in the study sample as a whole (p < 0.05). A trend was observed indicating that NTx may increase in individuals who have the greatest increases in prolactin after treatment r = 0.33, p = 0.07). These findings suggest that prolactin elevation is associated with changes in bone physiology very early in the course of treatment with risperidone. Bone resorption decreased in many subjects but higher levels of bone resorption occurred in patients with the greatest increases in prolactin. This may have important implications for prolactin monitoring or the periodic assessment of osteoporosis-related outcomes in patients requiring extended treatment.

Original languageEnglish (US)
Pages (from-to)95-102
Number of pages8
JournalTherapeutic Advances in Psychopharmacology
Volume2
Issue number3
DOIs
StatePublished - 2012

Fingerprint

Risperidone
Bone Remodeling
Prolactin
Bone Resorption
Therapeutics
Bone and Bones
Osteogenesis
Psychotic Disorders
Antipsychotic Agents
Osteoporosis
Collagen
Symptom Assessment
Osteocalcin
Major Depressive Disorder
Bipolar Disorder
Diagnostic and Statistical Manual of Mental Disorders
Bone Density
Testosterone
Estradiol
Schizophrenia

Keywords

  • antipsychotic
  • bone
  • prolactin
  • psychosis
  • risperidone

ASJC Scopus subject areas

  • Pharmacology, Toxicology and Pharmaceutics (miscellaneous)
  • Psychology (miscellaneous)

Cite this

Risperidone-associated prolactin elevation and markers of bone turnover during acute treatment. / Bishop, Jeffrey R.; Rubin, Leah H.; Reilly, James L.; Pavuluri, Mani N.; Sweeney, John A.

In: Therapeutic Advances in Psychopharmacology, Vol. 2, No. 3, 2012, p. 95-102.

Research output: Contribution to journalArticle

Bishop, Jeffrey R. ; Rubin, Leah H. ; Reilly, James L. ; Pavuluri, Mani N. ; Sweeney, John A. / Risperidone-associated prolactin elevation and markers of bone turnover during acute treatment. In: Therapeutic Advances in Psychopharmacology. 2012 ; Vol. 2, No. 3. pp. 95-102.
@article{d51a70b5f7cc4000810bb31a9c6004e8,
title = "Risperidone-associated prolactin elevation and markers of bone turnover during acute treatment",
abstract = "Prolactin elevation has been proposed as a risk factor for low bone density and potentially osteoporosis in patients on long-term treatment with prolactin-elevating antipsychotics. Our objective was to study the acute effects of prolactin elevation on serum markers of bone formation and resorption in patients treated with risperidone. Thirty participants meeting Diagnostic and Statistical Manual of Mental Disorders fourth edition criteria for schizophrenia, major depressive disorder with psychotic features, or bipolar disorder with psychosis were enrolled. At baseline, subjects were antipsychotic free. Subjects were evaluated before and after 4 weeks of risperidone treatment. Assessments included symptom ratings along with testosterone, estradiol, prolactin, osteocalcin (marker of bone formation), and n-telopeptide crosslinks (NTx marker of bone resorption). Primary analysis examined the impact of risperidone treatment on change in the bone markers and hormone levels from pre to post treatment. Prolactin levels significantly increased from 12.1 ± 1.9 ng/ml to 65.7 ± 12.2 ng/ml after treatment (p < 0.001). NTx markers of bone resorption significantly decreased from 18.31 ± 1.49 nM bone collagen equivalent (BCE) before treatment to 15.50 ± 1.22 nM BCE after treatment in the study sample as a whole (p < 0.05). A trend was observed indicating that NTx may increase in individuals who have the greatest increases in prolactin after treatment r = 0.33, p = 0.07). These findings suggest that prolactin elevation is associated with changes in bone physiology very early in the course of treatment with risperidone. Bone resorption decreased in many subjects but higher levels of bone resorption occurred in patients with the greatest increases in prolactin. This may have important implications for prolactin monitoring or the periodic assessment of osteoporosis-related outcomes in patients requiring extended treatment.",
keywords = "antipsychotic, bone, prolactin, psychosis, risperidone",
author = "Bishop, {Jeffrey R.} and Rubin, {Leah H.} and Reilly, {James L.} and Pavuluri, {Mani N.} and Sweeney, {John A.}",
year = "2012",
doi = "10.1177/2045125312442080",
language = "English (US)",
volume = "2",
pages = "95--102",
journal = "Therapeutic Advances in Psychopharmacology",
issn = "2045-1253",
publisher = "Sage Publications",
number = "3",

}

TY - JOUR

T1 - Risperidone-associated prolactin elevation and markers of bone turnover during acute treatment

AU - Bishop, Jeffrey R.

AU - Rubin, Leah H.

AU - Reilly, James L.

AU - Pavuluri, Mani N.

AU - Sweeney, John A.

PY - 2012

Y1 - 2012

N2 - Prolactin elevation has been proposed as a risk factor for low bone density and potentially osteoporosis in patients on long-term treatment with prolactin-elevating antipsychotics. Our objective was to study the acute effects of prolactin elevation on serum markers of bone formation and resorption in patients treated with risperidone. Thirty participants meeting Diagnostic and Statistical Manual of Mental Disorders fourth edition criteria for schizophrenia, major depressive disorder with psychotic features, or bipolar disorder with psychosis were enrolled. At baseline, subjects were antipsychotic free. Subjects were evaluated before and after 4 weeks of risperidone treatment. Assessments included symptom ratings along with testosterone, estradiol, prolactin, osteocalcin (marker of bone formation), and n-telopeptide crosslinks (NTx marker of bone resorption). Primary analysis examined the impact of risperidone treatment on change in the bone markers and hormone levels from pre to post treatment. Prolactin levels significantly increased from 12.1 ± 1.9 ng/ml to 65.7 ± 12.2 ng/ml after treatment (p < 0.001). NTx markers of bone resorption significantly decreased from 18.31 ± 1.49 nM bone collagen equivalent (BCE) before treatment to 15.50 ± 1.22 nM BCE after treatment in the study sample as a whole (p < 0.05). A trend was observed indicating that NTx may increase in individuals who have the greatest increases in prolactin after treatment r = 0.33, p = 0.07). These findings suggest that prolactin elevation is associated with changes in bone physiology very early in the course of treatment with risperidone. Bone resorption decreased in many subjects but higher levels of bone resorption occurred in patients with the greatest increases in prolactin. This may have important implications for prolactin monitoring or the periodic assessment of osteoporosis-related outcomes in patients requiring extended treatment.

AB - Prolactin elevation has been proposed as a risk factor for low bone density and potentially osteoporosis in patients on long-term treatment with prolactin-elevating antipsychotics. Our objective was to study the acute effects of prolactin elevation on serum markers of bone formation and resorption in patients treated with risperidone. Thirty participants meeting Diagnostic and Statistical Manual of Mental Disorders fourth edition criteria for schizophrenia, major depressive disorder with psychotic features, or bipolar disorder with psychosis were enrolled. At baseline, subjects were antipsychotic free. Subjects were evaluated before and after 4 weeks of risperidone treatment. Assessments included symptom ratings along with testosterone, estradiol, prolactin, osteocalcin (marker of bone formation), and n-telopeptide crosslinks (NTx marker of bone resorption). Primary analysis examined the impact of risperidone treatment on change in the bone markers and hormone levels from pre to post treatment. Prolactin levels significantly increased from 12.1 ± 1.9 ng/ml to 65.7 ± 12.2 ng/ml after treatment (p < 0.001). NTx markers of bone resorption significantly decreased from 18.31 ± 1.49 nM bone collagen equivalent (BCE) before treatment to 15.50 ± 1.22 nM BCE after treatment in the study sample as a whole (p < 0.05). A trend was observed indicating that NTx may increase in individuals who have the greatest increases in prolactin after treatment r = 0.33, p = 0.07). These findings suggest that prolactin elevation is associated with changes in bone physiology very early in the course of treatment with risperidone. Bone resorption decreased in many subjects but higher levels of bone resorption occurred in patients with the greatest increases in prolactin. This may have important implications for prolactin monitoring or the periodic assessment of osteoporosis-related outcomes in patients requiring extended treatment.

KW - antipsychotic

KW - bone

KW - prolactin

KW - psychosis

KW - risperidone

UR - http://www.scopus.com/inward/record.url?scp=84998179969&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84998179969&partnerID=8YFLogxK

U2 - 10.1177/2045125312442080

DO - 10.1177/2045125312442080

M3 - Article

VL - 2

SP - 95

EP - 102

JO - Therapeutic Advances in Psychopharmacology

JF - Therapeutic Advances in Psychopharmacology

SN - 2045-1253

IS - 3

ER -